Previous research demonstrated that HHLA2 exhibited primary expression on both tumor cell and antigen-presenting cell (APC) membranes [9–12], inhibiting human CD4+ and CD8+T cell proliferation and activation when T cell receptor signaling was present [9, 13, 14]. Here, HHLA2 is linked to neoplasm.